Rua Bioscience Limited (RUA.NZ)
NZD 0.03
(3.45%)
NZD 0.03
(3.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -13.3 Million NZD | 57.55% |
| 2023 | -11.42 Million NZD | -84.65% |
| 2022 | -6.62 Million NZD | -13.49% |
| 2021 | -5.8 Million NZD | -42.4% |
| 2020 | -3.93 Million NZD | -86.74% |
| 2019 | -2.14 Million NZD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - NZD | 63.95% |
| 2024 Q2 | -1.01 Million NZD | -968.98% |
| 2024 Q4 | 1.15 Million NZD | 0.0% |
| 2024 Q1 | -1.01 Million NZD | 84.79% |
| 2023 FY | - NZD | -84.65% |
| 2023 Q2 | -1.58 Million NZD | 0.0% |
| 2023 Q4 | -4.11 Million NZD | -0.36% |
| 2023 Q1 | -1.58 Million NZD | 15.49% |
| 2023 Q3 | -4.09 Million NZD | -159.31% |
| 2022 Q1 | -1.61 Million NZD | -28.46% |
| 2022 FY | - NZD | -13.49% |
| 2022 Q4 | -1.87 Million NZD | 0.62% |
| 2022 Q3 | -1.88 Million NZD | -16.86% |
| 2022 Q2 | -1.61 Million NZD | 0.0% |
| 2021 FY | - NZD | -42.4% |
| 2021 Q4 | -1.25 Million NZD | 8.18% |
| 2021 Q3 | -1.36 Million NZD | 19.66% |
| 2021 Q2 | -1.7 Million NZD | 0.0% |
| 2021 Q1 | -1.7 Million NZD | -53.12% |
| 2020 FY | - NZD | -86.74% |
| 2020 Q2 | -1.01 Million NZD | 0.0% |
| 2020 Q4 | -1.11 Million NZD | 2.57% |
| 2020 Q1 | -1.01 Million NZD | 0.0% |
| 2020 Q3 | -1.13 Million NZD | -12.18% |
| 2019 FY | - NZD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AFT Pharmaceuticals Limited | 25.72 Million NZD | 151.719% |
| Greenfern Industries Limited | -1.45 Million NZD | -815.909% |